Attached files
| file | filename |
|---|---|
| EX-32.2 - CERTIFICATION - Kintara Therapeutics, Inc. | f10k2017ex32-2_delmar.htm |
| EX-32.1 - CERTIFICATION - Kintara Therapeutics, Inc. | f10k2017ex32-1_delmar.htm |
| EX-31.2 - CERTIFICATION - Kintara Therapeutics, Inc. | f10k2017ex31-2_delmar.htm |
| EX-31.1 - CERTIFICATION - Kintara Therapeutics, Inc. | f10k2017ex31-1_delmar.htm |
| EX-23.2 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - Kintara Therapeutics, Inc. | f10k2017ex23-2_delmar.htm |
| 10-K - ANNUAL REPORT - Kintara Therapeutics, Inc. | f10k2017_delmarpharma.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-189337) of DelMar Pharmaceuticals, Inc. and in the related prospectus, |
| (2) | Registration Statement (Form S-3 No. 333-213600) of DelMar Pharmaceuticals, Inc. and in the related prospectus, and |
| (3) | Registration Statement (Form S-3 No. 333-213601) pertaining to the registration of securities of DelMar Pharmaceuticals, Inc. and in the related prospectus; |
of our report dated September 27, 2017, with respect to the consolidated financial statements of DelMar Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of DelMar Pharmaceuticals, Inc. for the year ended June 30, 2017.
| Vancouver, Canada, | /s/ Ernst & Young LLP |
| September 27, 2017 | Chartered Professional Accountants |